Published in Am J Cardiol on January 14, 2012
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30
Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes. Am J Cardiovasc Dis (2013) 0.81
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation (2004) 4.13
High-density lipoprotein as a therapeutic target: a systematic review. JAMA (2007) 3.92
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2007) 3.48
Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol (2010) 3.18
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol (2013) 2.99
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation (2004) 2.79
Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation (2010) 2.62
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Cardiopulmonary resuscitation quality: [corrected] improving cardiac resuscitation outcomes both inside and outside the hospital: a consensus statement from the American Heart Association. Circulation (2013) 2.49
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (2007) 2.36
Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm (2009) 2.34
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Renal denervation to treat resistant hypertension: Guarded optimism. Cleve Clin J Med (2012) 2.24
Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation (2012) 2.17
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med (2005) 2.08
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
Enhanced prediction of mortality after percutaneous coronary intervention by consideration of general and neurological indicators. JACC Cardiovasc Interv (2011) 2.01
The FREEDOM trial: in appropriate patients with diabetes and multivessel coronary artery disease, CABG beats PCI. Cleve Clin J Med (2013) 2.01
Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv (2005) 2.00
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol (2006) 2.00
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res (2010) 1.84
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol (2004) 1.77
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv (2009) 1.77
Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol (2010) 1.76
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.74
Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med (2007) 1.72
Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion. J Am Coll Cardiol (2008) 1.68
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol (2012) 1.66
International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2011) 1.65
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2012) 1.65
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis (2008) 1.63
Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol (2011) 1.62
Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. Circulation (2002) 1.60
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol (2006) 1.60
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.59
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation (2002) 1.58
Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replacement. J Thorac Cardiovasc Surg (2009) 1.57
Initial experience with the Evolution mechanical dilator sheath for lead extraction: safety and efficacy. Heart Rhythm (2010) 1.55
Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation (2003) 1.55
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J (2005) 1.54
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J (2010) 1.52
Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med (2005) 1.49
Limitations of the MEDLINE database in constructing meta-analyses. Ann Intern Med (2010) 1.48
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting. J Am Coll Cardiol (2013) 1.48
Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol (2012) 1.48
Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. Hypertension (2012) 1.46
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials. J Hypertens (2014) 1.45
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv (2010) 1.45
Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study. Catheter Cardiovasc Interv (2012) 1.44
An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol (2008) 1.44
Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? Am Heart J (2006) 1.44
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis. JACC Cardiovasc Interv (2010) 1.43
Magnitude and consequences of missing the acute infarct-related circumflex artery. Am Heart J (2009) 1.42
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol (2003) 1.42
Percutaneous treatment of aortic valve stenosis. Cleve Clin J Med (2008) 1.41
Drug-eluting stents: the beginning of the end of restenosis? Cleve Clin J Med (2004) 1.41
Carotid stenting vs surgery: parsing the risk of stroke and MI. Cleve Clin J Med (2010) 1.41
Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis. Catheter Cardiovasc Interv (2010) 1.41
Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol (2009) 1.41
Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes (2014) 1.41
Cardiogenic shock in the setting of severe aortic stenosis: role of intra-aortic balloon pump support. Heart (2010) 1.40
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol (2004) 1.40
Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia. JACC Cardiovasc Interv (2009) 1.40
Options for managing severe aortic stenosis: a case-based review. Cleve Clin J Med (2013) 1.40
Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol (2005) 1.39
Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry. JACC Cardiovasc Interv (2011) 1.39